A method for preparing a liquid extract rich in phycocyanin from cyanobacteria or microalgae containing phycocyanin in solution, comprising a step of carrying out the cellular lysis of an aqueous suspension of said fresh cyanobacteria or microalgae, a step of macerating the lysate obtained, for several hours in a solution of divalent cations, while releasing the water-soluble molecules in the extracellular space, and one or more steps of clarifying and concentrating the suspension in order to isolate the water-soluble molecules, among them phycocyanin. This method is performed at a pH between 5 and 8.5, at room temperature, without drying. Of

The present invention generally relates to photocatalytic systems comprising graphene and associated methods. Some embodiments are directed to systems comprising one or more layers of graphene having a first surface and a second, opposed surface. A light-absorbing complex may be associated with the first surface of the one or more graphene layers, and an electron donor complex may be associated with the light-absorbing complex. A catalytic complex may be associated with the first surface or the second surface of the one or more graphene layers. For example, the catalytic complex may catalyze the formation of hydrogen gas, NADH, and/or NADPH.

The present invention generally relates to photocatalytic systems comprising graphene and associated methods. Some embodiments are directed to systems comprising one or more layers of graphene having a first surface and a second, opposed surface. A light-absorbing complex may be associated with the first surface of the one or more graphene layers, and an electron donor complex may be associated with the light-absorbing complex. A catalytic complex may be associated with the first surface or the second surface of the one or more graphene layers. For example, the catalytic complex may catalyze the formation of hydrogen gas, NADH, and/or NADPH.

A space-bred seawater Spirulina H11 strain. The strain exhibits high growth rate, capacity of simultaneously accumulating high contents of phycocyanin, Spirulina polysaccharides and -carotene, and excellent adaptability to outdoor environment, thus can be used to produce high-quality Spirulina powders, phycocyanin, Spirulina polysaccharides, and -carotene-rich Spirulina oil.

A space-bred seawater Spirulina H11 strain. The strain exhibits high growth rate, capacity of simultaneously accumulating high contents of phycocyanin, Spirulina polysaccharides and -carotene, and excellent adaptability to outdoor environment, thus can be used to produce high-quality Spirulina powders, phycocyanin, Spirulina polysaccharides, and -carotene-rich Spirulina oil.

The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.

Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.

Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.